PR Newswire
SAN DIEGO, March 14, 2018
SAN DIEGO, March 14, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today provided a corporate update and reported financial results for the fourth quarter and full-year ended December 31, 2017.
"We've made significant progress in 2017, achieving the clinical and corporate objectives we set forth as a new team," said Amit D. Munshi, president and CEO of Arena. "Our focus remains on advancing our potentially best-in-class or best-in-disease pipeline and driving further value in the Company. We look forward to the etrasimod Phase 2 data readout this month and are enthusiastic about the Phase 3 clinical program for ralinepag, which we expect to begin in the second half of 2018."
Pipeline Update
Ralinepag – Oral, next generation, selective prostacyclin receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH)
Etrasimod – Oral, next generation, selective sphingosine-1-phosphate (S1P) receptor modulator intended for the potential treatment of multiple immune and inflammatory diseases
APD371 – Oral, peripherally restricted, full agonist of the cannabinoid 2 (CB2) receptor intended for the potential treatment of visceral pain, specifically pain associated with Crohn's disease
Collaborations Update
Corporate Update
Financial Update
Fourth Quarter 2017 Financial Results
Full-Year 2017 Financial Results
At December 31, 2017, the Company's cash, cash equivalents and investments balance was $271.3 million and approximately 39.3 million shares of Arena common stock were outstanding.
Conference Call & Webcast Information
The Company will host a conference call and live webcast with the investment community today, Wednesday, March 14, 2018, at 8:30 a.m. EDT to discuss the financial results and provide a corporate update.
When: March 14, 2018, 8:30 a.m. EDT
Dial-in: (877) 643-7155 (United States) or (914) 495-8552 (International)
Conference ID: 2074279
Please join the conference call at least 10 minutes early to register. You can access the live webcast under the investor relations section of Arena's website at: www.arenapharm.com. A replay of the conference call will be archived under the investor relations section of Arena's website for 30 days shortly after the call.
About Arena Pharmaceuticals
Arena Pharmaceuticals is focused on developing novel, small molecule drugs with optimized receptor pharmacology and pharmacokinetics designed to deliver broad clinical utility across several therapeutic areas. Arena's proprietary pipeline includes potentially first- or best-in-class programs. The most advanced investigational clinical programs are ralinepag (APD811), which will be commencing a Phase 3 program for pulmonary arterial hypertension (PAH), and etrasimod (APD334), which is in Phase 2 for a broad range of immune and inflammatory conditions. Arena is also evaluating APD371 in Phase 2 for the treatment of pain associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries), Axovant Sciences GmbH (nelotanserin - Phase 2), Boehringer Ingelheim International GmbH (undisclosed target - preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® - marketed product).
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements may be identified by words such as "anticipated," "focus," "potential," "look forward to," "expect," "intended for," "entitled to," "planned," "designed to," and "will," and include, without limitation, statements about initiation, enrollment, results, data readouts and timing relating to ongoing and intended clinical trials; the potential of Arena's drug candidates; the planned sale of Arena's manufacturing operations in Zofingen, Switzerland; Arena's investment community conference call and webcast; and Arena's focus, goals, strategy, clinical programs, and collaborators. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the risk that we may need additional funds to advance all of our programs, and you and others may not agree with the manner we allocate our resources; risks related to developing and commercializing drugs; risks and uncertainties relating to cash and revenues that may be generated from product sales or other sources, including the impact of competition; the risk that Arena's revenues are based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of research, development and regulatory review is uncertain, and our drug candidates may not advance in development or be approved for marketing; enrolling patients in our ongoing and intended clinical trials is competitive and challenging; clinical trials and other studies may not proceed at the time or in the manner expected or at all; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; topline data may not accurately reflect the complete results of a particular study or trial; satisfactory resolution of litigation or other disagreements with others; government and third-party payor actions, including relating to reimbursement and pricing; risks related to relying on collaborative arrangements; the entry into or modification or termination of collaborative arrangements; and Arena's and third parties' intellectual property rights. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
[email protected]
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
[email protected]
646.627.8384
(Tables Follow)
Arena Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts) | ||||||||||||||||||
Three months ended |
Year ended |
|||||||||||||||||
December 31, |
December 31, |
|||||||||||||||||
2017 |
2016 |
2017 |
2016 |
|||||||||||||||
(unaudited) |
||||||||||||||||||
Revenues |
||||||||||||||||||
Collaboration and other revenue |
$ 14,193 |
$ 69,225 |
$ 19,632 |
$ 92,163 |
||||||||||||||
Royalty revenue |
1,171 |
— |
1,705 |
— |
||||||||||||||
Total revenues |
15,364 |
69,225 |
21,337 |
92,163 |
||||||||||||||
Operating Costs & Expenses |
||||||||||||||||||
Research & development |
20,711 |
11,567 |
70,988 |
63,782 |
||||||||||||||
General & administrative |
8,253 |
6,981 |
30,341 |
27,529 |
||||||||||||||
Litigation settlement expense, net |
— |
— |
11,975 |
— |
||||||||||||||
Restructuring charges |
— |
— |
— |
6,115 |
||||||||||||||
Total operating costs & expenses |
28,964 |
18,548 |
113,304 |
97,426 |
||||||||||||||
Total interest & other expense, net |
(670) |
(1,751) |
(3,887) |
(7,037) |
||||||||||||||
Income (loss) from continuing operations |
(14,270) |
48,926 |
(95,854) |
(12,300) |
||||||||||||||
Income (loss) from discontinued operations |
315 |
(10,612) |
3,122 |
(10,596) |
||||||||||||||
Net income (loss) |
(13,955) |
38,314 |
(92,732) |
(22,896) |
||||||||||||||
Less net loss attributable to noncontrolling interest in consolidated variable interest entity |
271 |
258 |
1,325 |
380 |
||||||||||||||
Net (income) loss attributable to stockholders of Arena |
$ (13,684) |
$ 38,572 |
$ (91,407) |
$ (22,516) |
||||||||||||||
Amounts attributable to stockholders of Arena: |
||||||||||||||||||
Income (loss) from continuing operations |
(13,999) |
49,184 |
(94,529) |
(11,920) |
||||||||||||||
Income (loss) from discontinued operations |
315 |
(10,612) |
3,122 |
(10,596) |
||||||||||||||
$ (13,684) |
$ 38,572 |
$ (91,407) |
$ (22,516) |
|||||||||||||||
Net income (loss) attributable to stockholders of Arena per share, diluted:1 |
||||||||||||||||||
Continuing operations |
$ (0.36) |
$ 2.02 |
$ (2.87) |
$ (0.49) |
||||||||||||||
Discontinued operations |
0.01 |
(0.43) |
0.10 |
(0.44) |
||||||||||||||
$ (0.35) |
$ 1.59 |
$ (2.77) |
$ (0.93) |
|||||||||||||||
Net income (loss) attributable to stockholders of Arena per share, diluted:1 |
||||||||||||||||||
Continuing operations |
$ (0.36) |
$ 2.02 |
$ (2.87) |
$ (0.49) |
||||||||||||||
Discontinued operations |
0.01 |
(0.44) |
0.10 |
(0.44) |
||||||||||||||
$ (0.35) |
$ 1.58 |
$ (2.77) |
$ (0.93) |
|||||||||||||||
Shares used in calculating net loss attributable to stockholders of Arena per share, basic1 |
39,268 |
24,333 |
32,990 |
24,313 |
||||||||||||||
Shares used in calculating net loss attributable to stockholders of Arena per share, diluted1 |
39,268 |
24,343 |
32,990 |
24,313 |
1 Comparative period data adjusted to give effect to Arena's June 2017 1-for-10 reverse stock split. |
Arena Pharmaceuticals, Inc. | ||||
Condensed Consolidated Balance Sheet Data | ||||
(In thousands) | ||||
December 31, 2017 |
December 31, 2016 |
|||
1 |
1 |
|||
Assets |
||||
Cash & cash equivalents |
$ 158,837 |
$ 90,712 |
||
Accounts receivable |
2,357 |
573 |
||
Insurance recovery receivable |
12,025 |
— |
||
Prepaid expenses & other current assets |
2,681 |
2,169 |
||
Total available for sale investments |
112,482 |
— |
||
Land, property & equipment, net |
30,131 |
35,109 |
||
Other non-current assets |
3,622 |
2,841 |
||
Total assets of disposal group held for sale |
17,140 |
37,606 |
||
Total assets |
$ 339,275 |
$ 169,010 |
||
Liabilities & Equity |
||||
Accounts payable & accrued liabilities |
$ 15,622 |
$ 9,559 |
||
Accrued litigation settlement |
24,000 |
— |
||
Total deferred revenues |
2,177 |
6,577 |
||
Total lease financing obligations & other long-term liabilities |
62,737 |
66,087 |
||
Total liabilities of disposal group held for sale |
27,595 |
46,392 |
||
Total equity |
207,144 |
40,395 |
||
Total liabilities & equity |
$ 339,275 |
$ 169,010 |
1 The Condensed Consolidated Balance Sheet Data has been derived from the audited financial statements as of that date. |
View original content with multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2017-financial-results-300613634.html
SOURCE Arena Pharmaceuticals, Inc.
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member